ClinicalTrials.gg
Active, not recruitingNCT05087056Updated Sep 28, 2026

Safety, Tolerability, and Immunogenicity of MenABCWY Administered on Different Dosing Schedules in Healthy Adolescents

A Phase 2 interventional study of MenABCWY vaccine and Placebo in Meningitis, Meningococcal, sponsored by GlaxoSmithKline. Active, not recruiting at 30 sites in 2 countries. Open to participants aged 11 Years to 14 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Prevention

How we know

Updated Sep 28, 2026First site in GermanyEnrollment updated+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
305
Allocation
Randomized
Ages
11 Years to 14 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 36 studies in Meningitis, Meningococcal with a site in United States — none open to participants now, 1 under way, none of them phase 3. Meningitis, Meningococcal · United States.

Enrollment
22nd of 33
305 · median 751
Started
2021
with 1 other
Phase 2
10 of 36
none open now
Registered
36th of 36
by date
Lead sponsor
4 of 36
GlaxoSmithKline

Among the 36 studies in Meningitis, Meningococcal with a site in United States, this one is the 22nd largest by enrollment of the 33 interventional ones that give a count, is one of 2 that started in 2021, is one of 10 in phase 2, and was the 36th registered.

Meningitis, Meningococcal

125 studies on the registry are indexed under Meningitis, Meningococcal; 10 are open to participants now.

Browse Meningitis, Meningococcal studies →

Open to participants now

None of the 36 studies in Meningitis, Meningococcal with a site in United States is open now. The open studies under Meningitis, Meningococcal, anywhere →

Who these studies take

Of the 5 Meningitis, Meningococcal studies recruiting now, none set no upper age limit and 5 stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.

This study: 11 Years to 14 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 36 studies in Meningitis, Meningococcal with a site in United States as a file.
02

Study summary

The purpose of this study is to assess the safety, tolerability, and immunogenicity of the combined meningococcal groups A, B, C, W and Y (MenABCWY) vaccine (GSK3536819A) intended to protect against invasive meningococcal disease (IMD) caused by all 5 meningococcal serogroups.

03

Conditions studied

  • Meningitis, Meningococcal

Keywords

  • MenABCWY
  • Safety
  • Tolerability
  • Immunogenicity
  • Healthy adolescents
  • Invasive meningococcal disease
04

Who can participate

Ages eligible
11 Years to 14 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants or/and participants' parent(s)/Legally Acceptable Representative(s) [LAR(s)] who, in the opinion of the investigator, can and will comply, with the requirements of the protocol.
  • Written or witnessed/thumb printed obtained from the participant/parent(s)/LAR(s) of the participant prior to performance of any study specific procedure.
  • Written informed assent obtained from the participant (if applicable) prior to performing any study specific procedure.
  • A male or female between, and including, 11 and 14 years of age (i.e. 14 years + 364 days) at the time of the first vaccination.
  • Healthy participants as established by medical history, physical examination and clinical judgment of the investigator before entering into the study.
  • Female participants of non- may be enrolled in the study. Non-childbearing potential is defined as pre-menarche, hysterectomy, bilateral-salpingectomy or bilateral ovariectomy.
  • Female participants of childbearing potential may be enrolled in the study, if the participant:

    • has practiced adequate for 30 days prior to first vaccination, and
    • has a negative pregnancy test* on the day of vaccination, and
    • has agreed to follow adequate contraception for 30 days before each of the 2 subsequent vaccinations and for 30 days after each vaccination * Urine samples for pregnancy testing will be collected from female participants of childbearing potential at Visit 1, Visit 3 and Visit 5 prior to the vaccination.

Exclusion criteria

Exclusion Criteria:

Medical conditions

  • Current or previous, confirmed or suspected disease caused by N. meningitidis.
  • Household contact with and/or intimate exposure to an individual with laboratory confirmed N. meningitidis infection within 60 days of enrolment.
  • Progressive, unstable or uncontrolled clinical conditions.
  • Clinical conditions representing a to intramuscular vaccination and blood draws.
  • Any neuroinflammatory, congenital neurological conditions, encephalopathies, seizures. History of febrile convulsions should not lead to exclusion.
  • History of any reaction or likely to be exacerbated by any component of the vaccine(s)/product(s).

    • Hypersensitivity, including allergy, to any component of vaccines, including diphtheria toxoid (CRM197) and latex medicinal products or medical equipment whose use is foreseen in this study.
  • Abnormal function or modification of the immune system resulting from:

    • disorders or immunodeficiency syndromes.
    • Systemic administration of (PO/IV/IM) for more than 14 consecutive days within 90 days prior to study vaccination. This will mean prednisone equivalent ≥20 mg/day for adult participants / ≥0.5 mg/kg/day with maximum 20 mg/day for paediatric participants. Inhaled and topical steroids are allowed.
    • Administration of antineoplastic and immunomodulating agents or radiotherapy within 90 days prior to study vaccination.
    • Administration of long-acting immune-modifying drugs at any time during the study period.
  • Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the participant due to participation in the study.

Prior/Concomitant therapy

  • Use of any or non-registered product (drug, vaccine or medical device) other than the study vaccine(s)/product(s) during the period starting 30 days before the first dose of study vaccine(s)/product(s) (Day -29 to Day 1), or planned use during the study period.
  • Previous vaccination with any meningococcal (MenB or MenACWY) vaccine at any time prior to / assent (as applicable) with the exception of meningococcal C (conjugated or polysaccharide) vaccination, if the last dose of MenC was received at ≤24 months of age.
  • Administration of immunoglobulins and/or any blood products or plasma derivatives during the period starting 3 months before the administration of study vaccine/product or planned administration before the next blood sampling visit.
  • Chronic administration (defined as more than 14 days in total) of or other immune-modifying drugs during the period starting 90 days prior to the first vaccine/product dose(s). For corticosteroids, this will mean prednisone equivalent ≥20 mg/day for adult participants / ≥0.5 mg/kg/day with maximum of 20 mg/day for paediatric participants. Inhaled and topical steroids are allowed.

Prior/Concurrent clinical study experience

  • Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational vaccine/product (drug or medical device).

Other exclusions

  • Child in care.
  • Pregnant or lactating female.
  • Female planning to become pregnant / planning to discontinue precautions during the windows reported in the inclusion criterion.
  • History of /current chronic alcohol abuse and/or drug abuse as determined by the investigator.
  • Any study personnel or immediate dependants, family, or household members.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
305 participants (actual)

Study arms

  • Experimental
    ABCWY-24 Group

    Participants receive 2 doses of the MenABCWY vaccine at Day 1 and Day 721, 1 dose of Placebo at Day 1441.

    Combination Product: MenABCWY vaccine · Combination Product: Placebo

  • Experimental
    ABCWY-48 Group

    Participants receive 2 doses of the MenABCWY vaccine at Day 1 and Day 1441, 1 dose of Placebo at Day 721.

    Combination Product: MenABCWY vaccine · Combination Product: Placebo

Interventions

  • Combination productMenABCWY vaccine

    Two doses of the MenABCWY vaccine, administered intramuscularly in the deltoid region of the non-dominant arm, on a 0-, 24-month schedule in the ABCWY-24 Group, and a 0-, 48-month schedule in the ABCWY-48 Group.

  • Combination productPlacebo

    Single dose of Placebo (saline solution in pre-filled syringe), administered intramuscularly in the deltoid region of the non-dominant arm, at Day 1441 in the ABCWY-24 Group, and at Day 721 in the ABCWY-48 Group.

06

What researchers measure

Primary outcomes

  1. Percentage of participants with human serum bactericidal assay (hSBA) titers ≥ lower limit of quantitation (LLOQ) for each N. meningitidis serogroup B indicator strains

    The immune response to 2 doses of the MenABCWY vaccine administered on a 0-, 24-month schedule, and a 0-, 48-month schedule is evaluated against each N. meningitidis serogroup B indicator strains.

    Time frame: At Baseline (Day 1)

  2. Percentage of participants with hSBA titers ≥ LLOQ for each N. meningitidis serogroup B indicator strains

    The immune response to 2 doses of the MenABCWY vaccine administered on a 0-, 24-month schedule, and a 0-, 48-month schedule is evaluated against each N. meningitidis serogroup B indicator strains.

    Time frame: At 1 month after the second dose of MenABCWY (Day 751 for the ABCWY-24 Group and Day 1471 for the ABCWY-48 Group)

  3. Percentage of participants with solicited administration site events

    The solicited administration site events include pain, redness, swelling and induration. Redness, swelling, and induration are summarized according to defined severity grading scales: None (0 to 24mm); Mild (25 to 50mm); Moderate (51 to 100mm); Severe (\>100mm). Injection site pain is summarized according to "mild", "moderate" or "severe".

    Time frame: During the 7 days (including the day of vaccination) following each vaccination (Vaccines administered at Day 1, Day 721 and Day 1441)

  4. Percentage of participants with solicited systemic events

    The solicited systemic events include fever, headache, nausea, myalgia, arthralgia and fatigue. Fever is defined as body temperature 38.0°C (100.4°F). The preferred location for measuring temperature in this study is the oral route. Solicited systemic events (except fever) are summarized according to "mild", "moderate" or "severe".

    Time frame: During the 7 days (including the day of vaccination) following each vaccination (Vaccines administered at Day 1, Day 721 and Day 1441)

  5. Percentage of participants with any unsolicited adverse events (AEs) including all serious adverse events (SAEs), AEs leading to withdrawal, adverse events of special interest (AESIs) and medically attended AEs

    An unsolicited AE is an AE that was not included in a list of solicited events and must have been spontaneously communicated by a participant/participant's parent(s)/ Legally Acceptable Representative(s) who has signed the informed consent. An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject or is an abnormal pregnancy outcome. AESIs are predefined AEs of scientific and medical concern specific to the product or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor can be appropriate, because such an event might warrant further investigation in order to characterise and understand it. Medically attended AEs are symptoms or illnesses requiring a hospitalisation, or an emergency room visit, or visit to/by a health care provider.

    Time frame: During the 30 days (including the day of vaccination) following each vaccination (Vaccines administered at Day 1, Day 721 and Day 1441)

  6. Percentage of participants with SAEs, AEs leading to withdrawal, AESIs and medically attended AEs

    An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject or is an abnormal pregnancy outcome. AESIs are predefined (serious or non-serious) AEs of scientific and medical concern specific to the product or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor can be appropriate, because such an event might warrant further investigation in order to characterise and understand it. Medically attended AEs are symptoms or illnesses requiring a hospitalisation, or an emergency room visit, or visit to/by a health care provider.

    Time frame: During the 6 months (including the day of vaccination) following the first vaccination (Vaccine administered at Day 1)

  7. Percentage of participants with SAEs, AEs leading to withdrawal, AESIs and medically attended AEs

    An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject or is an abnormal pregnancy outcome. AESIs are predefined (serious or non-serious) AEs of scientific and medical concern specific to the product or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor can be appropriate, because such an event might warrant further investigation in order to characterise and understand it. Medically attended AEs are symptoms or illnesses requiring a hospitalisation, or an emergency room visit, or visit to/by a health care provider.

    Time frame: During the 6 months (including the day of vaccination) following the second vaccination (Vaccine administered at Day 721)

Secondary outcomes

  1. Percentage of participants with hSBA titers ≥ LLOQ for N. meningitidis serogroups A, C, W and Y

    The immune response to 1 and 2 doses of the MenABCWY vaccine administered on a 0-, 24-month schedule, and a 0-, 48-month schedule is evaluated against N. meningitidis serogroups A, C, W and Y.

    Time frame: At Baseline (Day 1), 1 month after the first dose of MenABCWY (Day 31) and 1 month after second dose of MenABCWY (Day 751 for the ABCWY-24 Group and Day 1471 for the ABCWY-48 Group)

  2. Percentage of participants with hSBA titers ≥ LLOQ for each N. meningitidis serogroup B indicator strains and for serogroups A, C, W and Y

    The antibody persistence at 25 months after the second dose of the MenABCWY vaccine administered on a 0-, 24-month schedule is evaluated against each N. meningitidis serogroup B indicator strains and serogroups A, C, W and Y.

    Time frame: At 25 months after the second dose of MenABCWY (Day 1471 for the ABCWY-24 Group)

07

Study locations

30 sites
  • GSK Investigational Site
    Birmingham, Alabama 35205, United States
  • GSK Investigational Site
    Tucson, Arizona 85745-2696, United States
  • GSK Investigational Site
    Ventura, California 93003, United States
  • GSK Investigational Site
    Washington D.C., District of Columbia 20016, United States
  • GSK Investigational Site
    Miami, Florida 33156-7397, United States
  • GSK Investigational Site
    Miami, Florida 33173, United States
  • GSK Investigational Site
    Macon, Georgia 31210, United States
  • GSK Investigational Site
    Valparaiso, Indiana 84088, United States
  • GSK Investigational Site
    Nicholasville, Kentucky 40517, United States
  • GSK Investigational Site
    Haughton, Louisiana 71037, United States
  • GSK Investigational Site
    Missoula, Montana 59804, United States
  • GSK Investigational Site
    Missoula, Montana 80216, United States
  • GSK Investigational Site
    Grand Island, Nebraska 68803, United States
  • GSK Investigational Site
    Lincoln, Nebraska 68510, United States
  • GSK Investigational Site
    Omaha, Nebraska 68134, United States
  • GSK Investigational Site
    Binghamton, New York 13905-1118, United States
  • GSK Investigational Site
    Endwell, New York 13850, United States
  • GSK Investigational Site
    Charlotte, North Carolina 28226, United States
  • GSK Investigational Site
    Gresham, Oregon 97030, United States
  • GSK Investigational Site
    Charleston, South Carolina 29414-5834, United States
  • GSK Investigational Site
    Kingsport, Tennessee 37660, United States
  • GSK Investigational Site
    Austin, Texas 75024, United States
  • GSK Investigational Site
    Galveston, Texas 77555 1115, United States
  • GSK Investigational Site
    Layton, Utah 84037, United States
  • GSK Investigational Site
    Schönau, Bavaria 83471, Germany
  • GSK Investigational Site
    Bramsche, 49565, Germany
  • GSK Investigational Site
    Herxheim, 76863, Germany
  • GSK Investigational Site
    Leipzig, 16269, Germany
  • GSK Investigational Site
    Mannheim, 68309, Germany
  • GSK Investigational Site
    Schweigen-Rechtenbach, 76889, Germany
08

References and documents

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2021 (actual). Primary completion is estimated for Mar 2027, 63 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 8, 2021
First posted
Oct 21, 2021
StartActual
Nov 18, 2021
Primary completionEst.
Mar 10, 2027
CompletionEst.
Mar 10, 2027
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
24 sites added — first site in Germany
Show 24 added (18 United States, 6 Germany)
  • GSK Investigational Site · Birmingham, United States
  • GSK Investigational Site · Washington D.C., United States
  • GSK Investigational Site · Miami, United States
  • GSK Investigational Site · Miami, United States
  • GSK Investigational Site · Nicholasville, United States
  • GSK Investigational Site · Haughton, United States
  • GSK Investigational Site · Missoula, United States
  • GSK Investigational Site · Grand Island, United States
  • GSK Investigational Site · Lincoln, United States
  • GSK Investigational Site · Omaha, United States
  • GSK Investigational Site · Binghamton, United States
  • GSK Investigational Site · Endwell, United States
  • GSK Investigational Site · Gresham, United States
  • GSK Investigational Site · Charleston, United States
  • GSK Investigational Site · Kingsport, United States
  • GSK Investigational Site · Austin, United States
  • GSK Investigational Site · Galveston, United States
  • GSK Investigational Site · Layton, United States
  • GSK Investigational Site · Schönau, Germany
  • GSK Investigational Site · Bramsche, Germany
  • GSK Investigational Site · Herxheim, Germany
  • GSK Investigational Site · Leipzig, Germany
  • GSK Investigational Site · Mannheim, Germany
  • GSK Investigational Site · Schweigen-Rechtenbach, Germany
Sep 28, 2026
Enrollment
312→305
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    24 sites added — first site in Germany
    Show 24 added (18 United States, 6 Germany)
    • GSK Investigational Site · Birmingham, United States
    • GSK Investigational Site · Washington D.C., United States
    • GSK Investigational Site · Miami, United States
    • GSK Investigational Site · Miami, United States
    • GSK Investigational Site · Nicholasville, United States
    • GSK Investigational Site · Haughton, United States
    • GSK Investigational Site · Missoula, United States
    • GSK Investigational Site · Grand Island, United States
    • GSK Investigational Site · Lincoln, United States
    • GSK Investigational Site · Omaha, United States
    • GSK Investigational Site · Binghamton, United States
    • GSK Investigational Site · Endwell, United States
    • GSK Investigational Site · Gresham, United States
    • GSK Investigational Site · Charleston, United States
    • GSK Investigational Site · Kingsport, United States
    • GSK Investigational Site · Austin, United States
    • GSK Investigational Site · Galveston, United States
    • GSK Investigational Site · Layton, United States
    • GSK Investigational Site · Schönau, Germany
    • GSK Investigational Site · Bramsche, Germany
    • GSK Investigational Site · Herxheim, Germany
    • GSK Investigational Site · Leipzig, Germany
    • GSK Investigational Site · Mannheim, Germany
    • GSK Investigational Site · Schweigen-Rechtenbach, Germany
    Enrollment 312→305
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05087056
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Oct 21, 2021
Start date
Nov 18, 2021
Primary completion
Mar 10, 2027 (estimated)
Completion
Mar 10, 2027 (estimated)
Last update
Sep 28, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion